Prof Yi-Long Wu (Guangdong Lung Cancer Institute, Guangzhou, China) and Prof Caicun Zhou (Shanghai Pulmonary Hospital, Shanghai, China) discuss the GEMSTONE 301 and GEMSTONE 302 trials on sugemalimab versus placebo in non-small-cell lung cancer.
Read the full articles:
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301)
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302)
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Prof Yi-Long Wu (Guangdong Lung Cancer Institute, Guangzhou, China) and Prof Caicun Zhou (Shanghai Pulmonary Hospital, Shanghai, China) discuss the GEMSTONE 301 and GEMSTONE 302 trials on sugemalimab versus placebo in non-small-cell lung cancer.
Read the full articles:
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301)
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302)
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv